| 1. | Evaluation on efficacy and safety of candesartan ciexetil in treatment of mild - to - moderate essential hypertension
国产坎地沙坦酯胶囊治疗轻中度原发性高血压疗效和安全性的评价 |
| 2. | Candesartan is a highly selective angiotensin type receptor blocker , mainly used in the treatment of hypertension and heart failure
摘要坎地沙坦是一个高选择性血管紧张肽受体拮抗药，主要用于高血压和心力衰竭的治疗。 |
| 3. | These findings suggest that candesartan has dosage - dependent , anti - inflammatory effects that are mediated by suppression of nf - b actiation and chemokine expression
这些研究表明，坎地沙坦是剂量依赖性、抗炎作用是通过抑制nf - b的活性和趋化因子表达介导的。 |
| 4. | A large number of clinical trials showed that candesartan could reduce the cardiovascular mortality for heart failure and hospitalization for worsening heart failure
大量临床研究结果表明坎地沙坦可降低心力衰竭病人心血管死亡率和因心力衰竭加重的住院率。 |
| 5. | These findings suggest that candesartan has dosage - dependent , anti - inflammatory effects that are mediated by suppression of nf - b activation and chemokine expression
这些研究表明，坎地沙坦是剂量依赖性、抗炎作用是通过抑制nf - b的活性和趋化因子表达介导的。 |
| 6. | Conclusions : the addition of spironolactone to candesartan has significant beneficial effects on lv reverse remodeling in patients with mild - to - moderate chronic systolic hf
结论：坎地沙坦联合螺内酯治疗对轻中度慢性收缩性心力衰竭患者的lv逆重构有明显益处。 |
| 7. | This study examined the effects of long - term ( 14 mo ) administration of ultrahigh dosages of the angiotensin receptor blocker candesartan on the progression of renal injury in spontaneously hypertensie rats ( shr )
该研究调查了超高剂量的血管紧张素受体阻滞剂坎地沙坦对自发性高血压大鼠的肾损伤进展的长期效应（ 14个月） 。 |
| 8. | This study examined the effects of long - term ( 14 mo ) administration of ultrahigh dosages of the angiotensin receptor blocker candesartan on the progression of renal injury in spontaneously hypertensive rats ( shr )
该研究调查了超高剂量的血管紧张素受体阻滞剂坎地沙坦对自发性高血压大鼠的肾损伤进展的长期效应（ 14个月） 。 |
| 9. | Methods : fifty - one systolic hf patients with left ventricular ejection fraction ( lvef ) < 40 % were randomly assigned to receive 1 - year treatment of candesartan and spironolactone ( combination group ) or candesartan and placebo ( control group )
方法： 51名左室射血分数（ lvef ） < 40 %的收缩性心力衰竭患者随机分配到接受坎地沙坦和螺内酯治疗1年（联合治疗组）或坎地沙坦和安慰剂治疗（对照组） 。 |
